Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Molgramostim in Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
2024-512039-66-00Phase 3Authorised
- Sponsor
- Savara
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Primary endpoint: Change in Hb-adjusted % predicted DLCO from Baseline to Week 24. Planned start Apr 2025; status: authorised.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on 2024-512039-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512039-66-00.